CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (32,609)	$ (19,711)	$ (26,558)
Adjustments to reconcile net loss to cash used in operating activities:
Impairment of intangible assets	78	176	1,142
Impairment of Panacea investment		1,741
Amortization and depreciation	999	1,094	1,186
Amortization of license fees	249	251	239
Amortization of ROU assets	288	182	212
Unrealized (gain) loss on investment	6,994	434	2,419
Realized (gain) loss on short-term investment securities		(5)	(221)
Litigation settlement			1,891
Gain on the sale of machinery and equipment		(1)	(87)
Gain on Panacea investment conversion	(2,548)
Accretion of non-cash interest expense (income)	143	(326)	26
Equity-based employee compensation expense	3,983	1,654	3,540
Inventory write-off	317	521	985
(Increase) decrease in assets:
Accounts receivable	1,574	(1,292)	4
Inventory	(1,164)	(289)	(207)
Prepaid expenses and other assets	(547)	(787)	280
Increase (decrease) in liabilities:
Operating lease obligations	(272)	(552)	(212)
Accounts payable	11	(936)	(732)
Accrued expenses	533	499	243
Accrued payroll	47	1,121	498
Accrued excise taxes and fees	(421)	563	51
Accrued severance	(341)	(225)	792
Deferred income	(153)	267	(78)
Net cash provided by (used in) operating activities	(22,839)	(15,621)	(14,588)
Cash flows from investing activities:
Acquisition of patents, trademarks, and licenses	(326)	(468)	(565)
Acquisition of property, plant and equipment	(745)	(54)	(527)
Proceeds from the sale of machinery and equipment		6	166
Investment in Panacea			(12,000)
Sales and maturities of short-term investment securities	63,749	39,728	19,320
Purchase of short-term investment securities	(90,407)	(22,743)	(1,842)
Net cash provided by (used in) investing activities	(27,729)	16,469	4,552
Cash flows from financing activities:
Payment on note payable	(2,604)	(2,549)	(700)
Proceeds from note payable issuance	2,653	2,195
Net proceeds from option exercises	1,307	50
Net proceeds from warrant exercises	11,782		10,616
Net proceeds from issuance of common stock	38,206
Taxes paid related to net share settlement of RSUs	(469)
Proceeds from SBA loan		1,183
Repayment of SBA loan		(1,183)
Net cash provided by (used in) financing activities	50,875	(304)	9,916
Net increase (decrease) in cash and cash equivalents	307	544	(120)
Cash and cash equivalents - beginning of period	1,029	485	605
Cash and cash equivalents - end of period	1,336	1,029	485
Net cash paid for:
Cash paid during the period for interest	37	29	3
Non-cash transactions:
Patent and trademark additions included in accounts payable	51	55	155
Property, plant and equipment additions included in accounts payable	998	2
Right-of-use assets and corresponding operating lease obligations	1,816	198	814
Patent and trademark additions included in accrued expenses	25	$ 28
Stock issued in connection with investment			$ 1,297
Panacea investment conversion	$ 12,485